spacer
home > ebr > winter 2001 > the german biotechnology industry - where does it stand globally and what are the obstacles to expansion?
PUBLICATIONS
European Biopharmaceutical Review

The German Biotechnology Industry - Where Does it Stand Globally and What Are the Obstacles to Expansion?

The global biotechnology industry has just taken its first steps towards an exponential growth development with potential sales that may amount to US$100 billion in 2005. Germany in particular has recently made extraordinary efforts to participate in this development. Currently, there are more than 2,600 biotech companies worldwide, with approximately the same number in the US as in Europe. The German biotech scene looks set for an exceptional and dynamic growth which has been significantly supported by the following political reforms:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Peter Heinrich, CEO of MediGene AG and Co-Founder and
Deputy Chairman of the Association of German Biotechnology Companies (VBU)

Dr Peter Heinrich studied Biology and Chemistry at the University of Munich. After receiving his doctorate in Biochemistry he worked from 1987 to 1988 as a postdoctoral scientist at Harvard University. Thereafter, he joined Wacker Chemicals - then a subsidiary of Hoechst AG - where he worked in different research and managerial positions. He left Wacker in 1995 to co-found MediGene GmbH and became its Chief Executive. In 1996 he was appointed Chief Executive Officer of MediGene AG. Since January 2001 Peter has also been President and Chief Executive Officer of the newly acquired MediGene Inc., San Diego (US).
In addition, Peter is a Co-Founder and Deputy Chairman of the Association of German Biotechnology Companies (VBU); a member of the executive board of the 'Gesellschaft fьr Chemische Technik und Biotechnologie e.V.' (DECHEMA); he serves on the board of the Emerging Biopharmaceutical Enterprises (EBE); and is an active member of the Bavarian Elite Academy.

spacer
Dr Peter Heinrich
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Essentra Packaging underlines quality and service with high-performance paper sack range

Essentra Packaging, Bangor (NI), producers of multiwall paper sacks, has shared its perspective on the soaring demand for paper sack packaging, the forces it believes are driving this growth, and how its paper sack range is adding value for brand owners.
More info >>

White Papers

Financial implications of off-site visits in clinical research, perception versus reality

Illingworth Research

The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off-site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off-site nursing more expensive than the traditional site model?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement